CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)         On December 16, 2016, the Compensation and Organization Development Committee of Cyclacel Pharmaceuticals, Inc. (the “Company”) approved the extension of the employment agreements (each “Employment Agreement” being extended by an “Extension Agreement”) with Spiro Rombotis, the President and Chief Executive Officer of the Company, and Paul McBarron, the Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer of the Company, such Extension Agreements to be effective as of January 1, 2017.

The terms of Mr. Rombotis’s Employment Agreement, which were previously disclosed under cover of Current Reports on Form 8-K filed on March 21, 2008, December 14, 2010, and March 21, 2014, remain unchanged, except that the term has been extended for another six months, through June 30, 2017.

The terms of Mr. McBarron’s Employment Agreement, which were previously disclosed under cover of Current Reports on Form 8-K filed on April 2, 2008, December 14, 2010, and March 21, 2014, remain unchanged, except that the term has been extended for another six months, through June 30, 2017.

Copies of the Extension Agreements will be filed as exhibits to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Recent Trading Information

CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) closed its last trading session down -0.05 at 3.95 with 60,161 shares trading hands.